Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Total Current Liabilities (2024 - 2025)

Historic Total Current Liabilities for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $56.4 million.

  • Xilio Therapeutics' Total Current Liabilities rose 4833.78% to $56.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.4 million, marking a year-over-year increase of 4833.78%. This contributed to the annual value of $27.3 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Xilio Therapeutics' Total Current Liabilities is $56.4 million, which was up 4833.78% from $53.3 million recorded in Q2 2025.
  • Xilio Therapeutics' 5-year Total Current Liabilities high stood at $56.4 million for Q3 2025, and its period low was $27.3 million during Q4 2024.